<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753570</url>
  </required_header>
  <id_info>
    <org_study_id>G060-F1</org_study_id>
    <nct_id>NCT01753570</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Na誰ve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)</brief_title>
  <official_title>A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Na誰ve or Have Received Interferon Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toray Industries, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients
      with genotype 1/2 hepatitis C, who are treatment-na誰ve or have received its treatment before.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 weeks after completion of drug administration (SVR, sustained viral response)</measure>
    <time_frame>72 weeks(Genotype 1 groups), 48 weeks(Genotype 2 group)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA at 4 weeks after beginning of drug administration (RVR, rapid viral response)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA at completion of drug administration (ETR, end-of-treatment response)</measure>
    <time_frame>24 weeks(Genotype 1 groups), 24 weeks(Genotype 2 group)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetectable HCV RNA at 12 weeks after completion of drug administration</measure>
    <time_frame>60 weeks(Genotype 1 groups), 36 weeks(Genotype 2 group)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transition of serum HCV RNA levels</measure>
    <time_frame>From baseline to 24 weeks after completion of drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral sequencing at the NS-3 protease region of HCV virus</measure>
    <time_frame>From baseline to 24 weeks after completion of drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Chronic Hepatitis C(CHC)</condition>
  <arm_group>
    <arm_group_label>MP-424(+RBV+IFN), Genotype1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RBV+IFN, Genotype1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MP-424(+RBV+IFN), Genotype2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MP-424</intervention_name>
    <description>MP-424: 750mg every 8 hours (q8h) for 12 weeks</description>
    <arm_group_label>MP-424(+RBV+IFN), Genotype1</arm_group_label>
    <arm_group_label>MP-424(+RBV+IFN), Genotype2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>RBV: 600 - 1000 mg/day based on body weight for 48 weeks</description>
    <arm_group_label>MP-424(+RBV+IFN), Genotype1</arm_group_label>
    <arm_group_label>RBV+IFN, Genotype1</arm_group_label>
    <arm_group_label>MP-424(+RBV+IFN), Genotype2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFN beta</intervention_name>
    <description>IFN: 600 MIU/day, 6 days/week for initial 4 weeks following to 3 days/week</description>
    <arm_group_label>MP-424(+RBV+IFN), Genotype1</arm_group_label>
    <arm_group_label>RBV+IFN, Genotype1</arm_group_label>
    <arm_group_label>MP-424(+RBV+IFN), Genotype2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genotype 1 or 2, chronic hepatitis C, with depression(including the past)

          -  treatment-na誰ve or patient who have ever had previous treatment

          -  Able and willing to follow contraception requirements

        Exclusion Criteria:

          -  Cirrhosis of the liver or hepatic failure

          -  Hepatitis B surface antigen-positive or HIV antibodies-positive

          -  History of, or concurrent hepatocellular carcinoma

          -  History of, or concurrent serious depression, schizophrenia,; or suicide attempt in
             the past

          -  Pregnant, lactating, or suspected pregnant patients, or male patients whose female
             partner is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuoki Kondo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toranomon Hospital</name>
      <address>
        <city>Kawasaki City</city>
        <state>Takatsu-ku</state>
        <zip>213-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2012</study_first_submitted>
  <study_first_submitted_qc>December 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Feron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 20, 2017</submitted>
    <returned>December 14, 2017</returned>
    <submitted>January 5, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

